Alpha-Synuclein Antibodies to Block Aggregate Spreading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases associated with alpha-synuclein aggregates, such as Parkinson's disease, are limited to symptomatic therapies, and there is a lack of effective diagnostic biomarkers for these conditions.
Innovation Solution
Development of alpha-synuclein binding molecules, particularly antibodies or their antigen-binding fragments, that inhibit and delay the aggregation of alpha-synuclein, recognizing and binding to pathological forms of the protein both in vitro and in vivo, thereby blocking cell-to-cell spreading and reducing pathological alpha-synuclein levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If symptomatic therapies are used for Parkinson's disease, then patient symptoms can be managed, but the underlying disease progression cannot be halted and no effective diagnostic biomarkers are available
Solution Approach 1:
The patent develops alpha-synuclein binding molecules (antibodies) that serve multiple functions: they act as therapeutic agents to inhibit aggregation and delay disease progression, while simultaneously serving as diagnostic biomarkers for detecting alpha-synuclein aggregates. This multi-functional approach resolves the contradiction by providing both disease management and diagnostic capabilities through a single molecular tool.
2Stability of the object's composition
If alpha-synuclein aggregation is left unchecked, then disease progression continues, but current treatments cannot effectively inhibit or delay this aggregation
Solution Approach 1:
The patent employs antibodies that perform preliminary anti-action by binding to alpha-synuclein aggregates before they can cause significant damage and spread. The antibodies inhibit aggregation processes and delay disease progression by neutralizing pathological alpha-synuclein forms in advance, preventing rather than merely responding to aggregate formation.
3Speed
If alpha-synuclein aggregates spread cell-to-cell, then disease progresses to new brain regions, but no mechanism exists to block this spreading
Solution Approach 1:
The patent uses alpha-synuclein binding molecules as intermediaries that block the spread of pathological alpha-synuclein between cells. The antibodies act as mediators by binding to aggregates and preventing their transfer to neighboring cells, thereby interrupting the cell-to-cell propagation mechanism and slowing disease progression to new brain regions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These molecules effectively inhibit and delay alpha-synuclein aggregation, reducing its pathological spread and levels, offering potential therapeutic benefits and diagnostic utility for diseases like Parkinson's disease and Lewy Body dementia.
Implementation Method 1
capable of recognizing and binding to pathological and/or aggregated alpha-synuclein
Data Source
AI summary
The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and/or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (a-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (FDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament.